UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D. C. 20549








FORM 10-Q/A








x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended January 31, 2011OR ̈
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934








Commission file number 000-53051





Advanced BioMedical Technologies, Inc.


(Exact name of registrant as specified in its charter)





Nevada


(State or other jurisdiction of incorporation or organization)





18 Lake Ridge Drive


Middletown, NY 10940


(Address of principal executive offices, including zip code.)





(718) 766-7898


(Registrant's telephone number, including area code)








Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES   x    NO    ̈




Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  YES    ̈    NO    ̈




Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act.




Large accelerated filer
 ̈

Accelerated filer
 ̈Non-accelerated filer
 ̈

Smaller reporting company
x




Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   YES    ̈    NO   x




As of June 17, 2011, there are 56,474,850 shares of common stock outstanding.
 
 All references in this Report on Form 10-Q to the terms “we”, “our”, “us”, the “Company”, “ABMT” and the “Registrant” refer to Advanced BioMedical Technologies, Inc. unless the context indicates another meaning.





EXPLANATORY NOTE:
 
 This amendment is filed for the purpose of amending Exhibits 31.1 and 31.2 to the Registrant’s Quarterly Report on Form 10-Q for the period ending January 31, 2011.










ITEM 6. EXHIBITS





The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:





Exhibit No.
Description31.1
Section 302 Certification of Chief Executive Officer*31.2
Section 302 Certification of Chief Financial Officer *





*filed herewith





SIGNATURES




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.








September 9, 2011





By:ADVANCED BIOMEDICAL TECHNOLOGIES, INC.By:
/s/ Chi Ming YUName:
Chi Ming YUTitle:
President and Director

(Principal Executive Officer)








By:
/s/ Wang HuiName:
Wang HuiTitle:
Director and Chief Executive Officer

(Controller)








By:
/s/ Kai GUIName:
Kai GUITitle:
Director, Secretary and Chief Financial Officer

(Principal Financial Officer)